

## *Accelerating deep-tech life science ventures with capital, IP, and scientific mentorship*




*Next-Gen Pheromones and Biological Agri-Inputs for Climate-Resilient Agriculture*



*Reimagining sweeteners with protein biology and low-GI fiber-rich alternatives*



*Revolutionising Obesity Care with First-in-Class Vaccine*



*Oncology breakthroughs for India with small molecules targeting AML and CML*



*Your daily system reboot—heals gut & gum, tastes like sugar, works like medicine*



*Redefining biological agriculture with biocontrol innovation – from pest to protein, lab to land*



*Advancing green chemistry with precision biocatalysis for sustainable manufacturing*

## WHALE TANK BIOCATALYST

Accelerating Deep Tech Innovation for  
Global Health & Sustainability



# India's Bio-E3 Vanguard

Whale Tank BioCatalyst LLP at Boston Bio 2025



## A Deep-Tech Platform Translating Synthetic Biology into Scalable Solutions for Agriculture, Health, and Nutrition

In an era defined by the need for climate-resilient agriculture, post-chemical health interventions, and sustainable food systems, **Whale Tank BioCatalyst LLP**, founded by **Dr. Markandeya Gorantla, Dr. Uday Saxena and Dr. VB Reddy** is emerging as one of India's most ambitious and globally aligned ventures. Based in Genome Valley, Hyderabad, and anchored at **ATGC Innovation Square**, Whale Tank is not just a fund or a holding company it is a **deep-tech translation engine**, strategically positioned to shape the next generation of biomanufacturing in line with India's **BIO-E3 policy**.

What sets Whale Tank apart is its model: it **invents, licenses, incubates, and commercializes** intellectual property born out of synthetic biology, material science, and behavioral biology. With a portfolio of seven companies from pheromone-based pest control to gut-healing sweeteners and precision oncology Whale Tank exemplifies how **science-led innovation from the Global South** can achieve global ESG, IP, and market relevance.




 [www.whaletank.in](http://www.whaletank.in)

## A Platform Built on Science, Strategy, and Sovereignty

At its core, Whale Tank represents **India's push for biostrategic sovereignty** investing in categories often neglected by Western VCs but critical for human and environmental health:

1. **Semiochemicals and Sustainable Pest Control** (ATGC Biotech)
2. **Preventive Vaccines for Chronic Diseases** ( Utopia Therapeutics)
3. **Natural Sweeteners. Functional Fibers. Synthetic Biology for Global Wellness** (Revelations Biotech )
4. **Regenerative Nutrition and Gut Health** (NexaSweet™ under Whale Tank)
5. **Low-Cost Precision Oncology** (BAT & AACT Inc.)
6. **Biocontrols and Post-Pesticide Agriculture Peptides, dsRNA, Baculoviruses** (ATREVA)
7. **Green Chemistry and Biocatalysis** (GreeSynZyme)

Each portfolio company is either a direct invention or a co-licensed technology integrated into a **shared biomanufacturing and regulatory backbone** — ATGC Innovation Square. This centralized execution model enables economies of scale, cross-pollination of IP, and rapid deployment across India, USA, LATAM, Africa, and Israel.



## ATGC Biotech Pvt. Ltd.


### ***“Future-Ready Farming with Smart Pheromone Technologies”***

ATGC Biotech Pvt. Ltd. is a globally recognized Indian company and a pioneer in carbon-neutral, bio-manufactured crop protection solutions that integrate synthetic biology and material science. Founded in 2011 and headquartered in Genome Valley, Hyderabad, ATGC is India's only commercial-scale manufacturer of pheromone-based behavioral insect biosimilars biologically produced molecules that disrupt mating communication between insect pests, thereby preventing reproduction and suppressing population growth.

Unlike monitoring pheromone traps, ATGC's technology operates at a field scale to confuse male insects using a competitive saturation mechanism rendering them unable to locate female partners and thereby breaking the pest lifecycle without any chemical kill.

ATGC refers to this disruptive strategy as **“Insect Family Planning”**, a sustainable, non-toxic alternative to conventional pesticides. These pheromone actives are manufactured using **whole-cell biotransformation** — a zero-energy, solvent-free microbial fermentation process and are delivered through advanced controlled-release systems such as glue dots, solid tablets, and sprayable microcapsules engineered using **mesoporous silica, carbon spheres, and cubosome dispersions**.

With **26 granted patents, 10+ national and international grants**, and validated deployment across over **200,000 acres** annually, ATGC has emerged as a flagship Indian innovator in sustainable agriculture and bio-based crop protection.



In 2024, the **World Economic Forum**, in collaboration with **BIRAC**, selected ATGC as a global case study under its **Regional Bioeconomy Workshop** series. The forum specifically recognized ATGC's leadership in transitioning pheromone-based behavioral disruption technologies previously used only in high-value horticulture into mainstream row crops like rice, sugarcane, and corn, enabling large-scale, cost-effective, and climate-resilient pest control.

ATGC's innovation trajectory has also been consistently acknowledged by India's premier science agencies. The company was named “**Innovator of the Year**” by DBT-BIRAC in both 2017 (CREMIT PBW) and 2018 (delivery systems), and was subsequently recognized by the **Ministry of Agriculture** in 2019 as the “**Company to Replace Insecticides**”, in line with national efforts to reduce pesticide residues and environmental toxicity in agriculture.

In 2025, the **Indian Academy of Sciences (IASc)** featured ATGC prominently in its white paper on chemoecological pest management, identifying the company as central to India's global leadership in pheromone and biocontrol innovation.

ATGC was also profiled in **Vigyan Dhara**, the flagship publication of the Principal Scientific Adviser to the Government of India, for its industrial scale-up of nano-enabled delivery systems developed in collaboration with **JNCASR** and **CSIR-NCL**.

Founded in 2011, ATGC has developed and exported over **50 pheromone molecules**, delivering more than **65 MT** of biomanufactured active ingredients to federal programs in the US, LATAM, and the Middle East. It is the only **non-US supplier to USDA's “Slow the Spread (STS)”** program.





# “Natural Sweeteners. Functional Fibers. Microbiome-First Solutions for Global Wellness.”

**Revelations Biotech** is a biotechnology company specializing in the **development, scale-up, and commercialization** of **natural sweeteners, prebiotic fibers, and fermented bioactives**, addressing the health-driven transformation of global food, beverage, nutraceutical, and pharmaceutical sectors.

The company's flagship products **FOS (Fructooligosaccharides) FOSLIFE**, **Brazzein**, and **Allulose** respond directly to rising global demands for **calorie control, gut health, and sugar replacement**, supporting regulatory and consumer shifts worldwide.



# Sweet Spot®



## Core Product Portfolio

### FOS – FOSLIFE Prebiotic Fiber

- Improves gut health, promotes bifidobacteria and lactobacilli growth
- Adopted by brands like Kellogg's, Haldiram's, Dabur, Patnajali, and Amul
- Used in cereals, traditional sweets, beverages, nutrition bars, and pharma supplements

### Brazzein – Natural High-Intensity Sweetener

- Up to 500x sweeter than sugar, zero-calorie, clean taste
- Under trials with PepsiCo, Hershey's, Nestlé, Amul, and others
- Applications in chocolates, confectionery, ice creams, and diet beverages

### Allulose – Rare Sugar with 10% Caloric Value

- 70% sweetness of sugar, 90% calorie reduction
- Being integrated into biscuits, snacks, yogurts, and beverages
- Highly compatible with diabetic and weight-management products



Sweet Spot®



**UTOPIA**  
therapeutics  
Redefining Chronic Care with Breakthrough Vaccines



*Revolutionising  
Obesity Care with*  
**First-in-Class Vaccine**



## The Problem

### Obesity & Its Comorbidities


### Obesity : The Biggest Unmet Medical Need After Cancer

#### The Global Epidemic

1.9 billion overweight adults, 650 million obese – leading to diabetes, heart disease, and fatty liver.

#### Current treatments have limitations

GLP-1 drugs (e.g., Ozempic) only suppress appetite.



### Revolutionary One-Shot Vaccine for Obesity & Fatty Liver

### A First-in-Class Vaccine Targeting Fat Metabolism, **Not Appetite**


#### How it works

##### The Global Epidemic

- **Activates Natural Fat Burning** – Targets Fatty Acid Pathway for sustained weight loss
- **Reduces fat accumulation in liver and visceral fat** as well as body weight and blood triglycerides
- **No Appetite Suppression, No Weight Rebound** – Works independently of hunger signals.

### Preclinical Success & Clinical Progress

### Stellar Animal Model Results-Moving to Human Trials



#### Breakthrough Data

- 42% Triglyceride Reduction-robust TG lowering as Leading Alternatives
- 24% Visceral Fat Reduction-directly impacts metabolic health
- Liver Fat Reduction – lowers the risk of NAFLD & metabolic disorders.

#### No Side Effects Observed in Preclinical Studies

- No Significant Side Effects-
- No Muscle Loss, No Appetite Suppression
- Long-lasting metabolic benefits even after stopping treatment.

### Regulatory & Clinical Progress

- IND-enabling studies in progress.
- Phase-I trials planned for 2025-2026.
- Fast-track pathways in India, Southeast Asia & the US.

### Collaboration

#### Open to Collaborate or Partner to :

- Advance UT009 into IND Enabling GLP Tox studies
- File IND with US-FDA, for clinical trial initiation.



**BHARATH  
ADVANCED  
THERAPEUTICS  
(BAT)**

*Revolutionizing Cancer Therapies in India*

## Bharath Advanced Therapeutics: Redefining Leukemia Treatment for Mutation-Driven Resistance

**Bharath Advanced Therapeutics Pvt. Ltd. (BAT)** is a next-generation oncology company solving one of the hardest challenges in leukemia treatment: **mutation-driven resistance**. Our lead candidate, **AA150030**, is a **first-in-class, dual FLT3/BCR-ABL inhibitor**, rationally engineered to tackle the **full spectrum of resistant mutations** in Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML).

### Mutation Coverage That Redefines the Standard

AA150030 uniquely combines high selectivity and sub-nanomolar potency against the following critical mutations:

#### **AML (FLT3 Mutations):**

- FLT3-ITD:  $IC_{50} < 1$  nM
- FLT3-D835Y:  $IC_{50} < 1$  nM

#### **CML (BCR-ABL Mutations):**

- T315I (multi-drug resistant gatekeeper mutation):  $IC_{50} = 51.21$  nM
- E255K, G250E, H396P, F317L, M351T, Q252H, Y253F, and others:  $IC_{50} = 1.14$ – $3.72$  nM

These mutations are responsible for **relapse, poor prognosis, and therapeutic failure** in standard care. AA150030 surpasses current options in both potency and breadth of action, with up to **300-fold greater potency** against these resistant mutants.

**Advancing Science, Transforming Lives.**



**BHARATH  
ADVANCED  
THERAPEUTICS  
(BAT)**

*Revolutionizing Cancer Therapies in India*

## Breakthrough Efficacy

- **100% tumor regression** in xenograft models of AML at doses as low as 50 mg/kg
- **No relapse** observed weeks after treatment cessation
- **Complete apoptosis induction** in FLT3-ITD AML cells (MV4-11) with **no toxicity** to normal cells at 100x doses

## Oral, Once-Daily, and Metabolically Stable

- **91% oral bioavailability, 8.3-hour half-life**, and **excellent Caco-2 permeability**
- **No CYP450 inhibition**, minimizing drug-drug interaction risk
- **Low-cost synthetic route** with <6 steps and no chiral centers

AA150030 is uniquely optimized for **once-daily oral dosing, global scalability**, and **cost-effective delivery**, especially in resource-constrained markets like India

## Designed for Clinical and Commercial Impact

- IND-enabling studies are in progress
- Phase I trials begin in **Q3 2025**, with expansion into FLT3+ AML and T315+ CML patients


## Backed by India-US Scientific Leadership

Founded by leaders from Mount Sinai (USA) and ATGC (India), BAT brings deep IND, clinical, and CMC expertise with 250+ years of combined experience. Supported by Indian manufacturing partners and funded by a consortium of pharma investors, BAT is poised to **transform the standard of care for leukemia in Asia and globally**.

**“AA150030 isn't just a new drug. It's a mutation-smart, relapse-proof blueprint for the future of leukemia therapy.”**

## Discover our Journey

Explore the in vivo success of our lead candidate, AA150030, driving new possibilities in cancer treatment.





# COMING SOON

✦ A sweet way to restore what life wears down. ✦

## Advanced Triple-Action Regenerative Nutraceutical

*Powered by proprietary UT18 Bioactive Stem Cell Homing & Prebiotic Dietary Fiber*

**Rebuild • Rebalance • Renew.**

Restore your gut health naturally and effectively.

## *The Future of Gut Wellness - Redefined*

### **UT18 Bioactive Complex**

A breakthrough attractant-based molecule that:

- Activates gut-immune signaling
- Modulates inflammation
- Restores mucosal integrity

### **Microbiome-Enhancing Agents**

- Encourages beneficial gut flora
- Supports digestion and nutrient absorption
- Improves microbiota diversity

**Together**, they work *synergistically* to rebuild your gut, rebalance your microbiome, and renew your vitality



**Presenting:**  
A revolutionary  
new way to  
reboot your  
system inside out.

## Clinical Functionality

### Repair

- Supports gut lining integrity
- May reduce “leaky gut” symptoms
- Encourages tissue regeneration

### Rebalance

- Promotes beneficial bacteria
- Enhances microbiota diversity
- Supports digestive rhythm

### Regulate

- Balances immune responses
- Modulates gut inflammation
- Strengthens gut-immune interface

### Manufactured by

Whale Tank BioCatalyst LLP

- ATGC Innovation Square, Genome Valley, Hyderabad



## Integrated Product Portfolio

ATREVA is the exclusive commercialization vehicle for the advanced biological innovations developed at the **Prof. Arjula Rama Chandra ATGC Bio Foundry**.

Our offerings include:

- **Baculoviruses:** Precision-targeted viral biocontrol agents for Lepidopteran pests
- **Entomopathogenic Nematodes (EPNs):** Natural soil-borne pest killers
- **Secondary Metabolites:** Novel microbial and fungal metabolites for systemic control
- **Pheromones:** Synthetic biology-derived formulations for mating disruption and mass trapping

Each product is developed using **CRISPR/Cas9**, synthetic biology, and advanced fermentation technologies to ensure **potency, environmental safety, and scalability**

ARR Foundation Brochure.



## Platform Integration for Field and Industry

- **Custom-designed Biocontrol Agents:** Pest-specific, non-toxic to beneficials
- **Optimized Microbial Strains:** Engineered for increased biopesticide expression
- **Scalable Biomanufacturing:** Modular bioreactors and low-cost fermentation lines
- **Formulation-Ready:** Liquid, capsule, tablet, and gel formats available
- **International Compatibility:** Products meet US, EU, and Indian regulatory standards

## Made in India, Built for the World

ATREVA is unlocking the full potential of India's:

- **Biodiversity** - tapping into underexplored microbes and invertebrate viruses
- **Biotech Research Ecosystem** - Supported by ICAR-NBAIR, JNCASR,
- **Manufacturing Infrastructure** - large-scale, export-compliant facilities
- **Low-Cost Innovation** - global-grade biocontrol at 1/5th the cost of imports

## Global Licensing & Strategic Reach

- **Partners across USA, Israel, EU, LATAM, and Africa**
- **High-throughput screening and AI-augmented pest-specific pipelines**
- **Joint ventures, white-labeled supply, and public-private partnerships**
- **Carbon-offset enabled deployment strategies for ESG-aligned agriculture**

## Sustainability + Socio-Economic Impact

- Replaces toxic chemicals in thousands of acres
- Builds rural biotech jobs and entrepreneurship
- Strengthens India's \$100M agri-bio sector into a **\$5B bioeconomy opportunity**
- Ensures **zero-residue, export-compliant agriculture** for the 21st century

**ATREVA is not just a product company. It is the future of biologically intelligent agriculture.**

From pest to protein, from lab to land — we are driving India's rise in the global bioeconomy.



# WHALE TANK BIOCATALYST

## Innovation Square

Sy. #494, 495, 496 & 500, Koltur (V), Shameerpet (M)  
Ranga Reddy, Medchal-Malkajgiri (Dt)-500 078  
Telangana, India.

+91 9866 023 556 / +91 9550 972 227

mg@whaletank.in

www.whaletank.in

## *Funding & Licensing Acknowledgement*

- Whale tank Portfolio companies

## *Supported by:*

- BioE<sup>3</sup> Program – DBT-BIRAC, Government of India  
Biomufacturing Hub Initiative
- DBT- BIRAC BIPP Grants to ATGC Products
- Family offices of Mr. Rajender Chadak and  
Mr. Rajesh Maggu

## *Whale tank Portfolio products*

### *Under License from:*

- Utopia Therapeutics (Stem Cell Homing – UT18 Technology)
- Revelations Biotech

## *The Founding Principles & Partners*

- **Dr. Markandeya Gorantla**, Founder, Expert in Deep Tech  
in Agri and Drug Discovery.
- **Dr. Uday Saxena**, Ex Pfizer/VP R and D AtheroGenics Inc  
(NASDAQ), CSO Dr. Reddy's Laboratories, Chair - BAT, Co  
Founder
- **Dr VB Reddy**, Ex CSO Agrigenome - Scientific founder
- **Mr. Rolando Alegria**, Strategy and Marketing
- **Dr. Jagadeesh Gandla**, COO, Whale Tank  
FABA Life Science Fund
- **Dr. Mamta S.K**, Ph.D. Scientific DIRECTOR WT-Biocatalyst
- **Mr. Niraj Chandak**, Partner

## *FABA knowledge partner*

- **Prof. Reddana P**, President of FABA, Leading the  
Knowledge Partner Initiative
- **Dr. Ratnakar**, Secretary of FABA, Contributing to Strategic  
Mentorship s

